Prognostic Value Of Pathologic Complete Response And The Alteration Of Breast Cancer Immunohistochemical Biomarkers After Neoadjuvant Chemotherapy

Neoadjuvant chemotherapy can provide information about the tumor's sensitivity to chemotherapy and assess individualized prognostic significance based on response to therapy.The biomarkers are key factors in the decision-making process regarding neoadjuvant therapy as well as important prognostic indicators.The pathologic complete response(p CR)after NCT has demonstrated with an associated survival benefit.For the patients who do not achieve p CR,the pathologic characteristics of the residual tumor can predict the survival.Furthermore,the immunohistochemical(IHC)markers of the residual diseases after primary systemic therapy might be different from the primary tumor.Estrogen receptor(ER),progesterone receptor(PR),and Ki67 can usually change after neoadjuvant therapy,while human epidermal growth factor receptor 2(HER2)seems to be more stable.Triple-negetive breast cancer is currently the breast cancer subtype with the worst outcome and comprise the largest group of patients whose receptor status did not change.However,the association between the alterations in receptor status after NCT and long-term survival outcomes is not clear.This article will make a review about whether p CR can accurately predict the prognosis and the relationship between the changes in the molecular classification of residual disease and prognosis after neoadjuvant chemotherapy in breast cancer.